A phase 1/2a first-in-human study of AFM24, a CD16A/epidermal growth factor (EGFR) bispecific Innate Cell Engager (ICE®), in patients with locally advanced or metastatic EGFR-expressing solid tumors: Preliminary findings from the dose-escalation phase

Authors
Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: e90362b8cecbe7bb2e33bddbf474e52e7c210940
First added on: Feb 14, 2025